Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells.
Ladell K, Hashimoto M, Iglesias MC, Wilmann PG, McLaren JE, Gras S, Chikata T, Kuse N, Fastenackels S, Gostick E, Bridgeman JS, Venturi V, Arkoub ZA, Agut H, van Bockel DJ, Almeida JR, Douek DC, Meyer L, Venet A, Takiguchi M, Rossjohn J, Price DA, Appay V. Ladell K, et al. Among authors: venet a. Immunity. 2013 Mar 21;38(3):425-36. doi: 10.1016/j.immuni.2012.11.021. Immunity. 2013. PMID: 23521884 Free article.
Identification of a particular HIV-specific CD8+ T-cell subset with a CD27+ CD45RO-/RA+ phenotype and memory characteristics after initiation of HAART during acute primary HIV infection.
Lécuroux C, Girault I, Urrutia A, Doisne JM, Deveau C, Goujard C, Meyer L, Sinet M, Venet A. Lécuroux C, et al. Among authors: venet a. Blood. 2009 Apr 2;113(14):3209-17. doi: 10.1182/blood-2008-07-167601. Epub 2008 Dec 19. Blood. 2009. PMID: 19098272 Free article. Clinical Trial.
Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection.
Lacabaratz-Porret C, Urrutia A, Doisne JM, Goujard C, Deveau C, Dalod M, Meyer L, Rouzioux C, Delfraissy JF, Venet A, Sinet M. Lacabaratz-Porret C, et al. Among authors: venet a. J Infect Dis. 2003 Mar 1;187(5):748-57. doi: 10.1086/368333. Epub 2003 Feb 18. J Infect Dis. 2003. PMID: 12599048 Clinical Trial.
Antiretroviral therapy initiation during primary HIV infection enhances both CD127 expression and the proliferative capacity of HIV-specific CD8+ T cells.
Lécuroux C, Girault I, Boutboul F, Urrutia A, Goujard C, Meyer L, Lambotte O, Chaix ML, Martinez V, Autran B, Sinet M, Venet A; ANRS PRIMO Cohort, ANRS HIC Study Group; ANRS ALT Cohort; ANRS HIC Study Group. Lécuroux C, et al. Among authors: venet a. AIDS. 2009 Aug 24;23(13):1649-58. doi: 10.1097/QAD.0b013e32832e6634. AIDS. 2009. PMID: 19617814
Natural history of HIV-control since seroconversion.
Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d'Arminio Monforte A, Amornkul P, Bartmeyer B, Sannes M, Venet A, Lambotte O, Meyer L; CASCADE Collaboration in Eurocoord. Madec Y, et al. Among authors: venet a. AIDS. 2013 Sep 24;27(15):2451-60. doi: 10.1097/01.aids.0000431945.72365.01. AIDS. 2013. PMID: 23912979
Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study.
Noel N, Lerolle N, Lécuroux C, Goujard C, Venet A, Saez-Cirion A, Avettand-Fenoël V, Meyer L, Boufassa F, Lambotte O; ANRS C021 CODEX Study Group. Noel N, et al. Among authors: venet a. PLoS One. 2015 Jul 6;10(7):e0131922. doi: 10.1371/journal.pone.0131922. eCollection 2015. PLoS One. 2015. PMID: 26146823 Free PMC article.
108 results